摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3H-咪唑并[4,5-B]吡啶-6-醇 | 1023815-26-0

中文名称
3H-咪唑并[4,5-B]吡啶-6-醇
中文别名
3H-咪唑并[4,5-b]吡啶-6-醇
英文名称
3H-Imidazo[4,5-b]pyridin-6-ol
英文别名
1H-imidazo[4,5-b]pyridin-6-ol
3H-咪唑并[4,5-B]吡啶-6-醇化学式
CAS
1023815-26-0
化学式
C6H5N3O
mdl
MFCD09881287
分子量
135.12
InChiKey
JLKCVUZFBPLUQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    512.7±30.0 °C(Predicted)
  • 密度:
    1.557±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    61.8
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

文献信息

  • Fused ring 4-oxopyrimidine derivative
    申请人:Nagase Tsuyoshi
    公开号:US20050182045A1
    公开(公告)日:2005-08-18
    The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X 1 is a nitrogen atom, sulfur atom or oxygen atom, R 1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R 2 and R 3 are amino groups or alkylamino groups, and X 2 is represented by formula (II): (where R 4 and R 5 are lower alkyl groups, and n is an integer from 2 to 4).]
    本发明提供以下公式(I)所表示的化合物或其药学上可接受的盐,具有组织胺H3受体拮抗剂或逆激动剂活性,在代谢性疾病、循环系统疾病或神经系统疾病的预防或治疗中有用。【其中,例如,Ar是通过从苯中消除两个氢原子形成的二价基团,X1是氮原子、硫原子或氧原子,R1是5-至6-成员杂芳基团,环A是5-至6-成员杂芳基环,R2和R3是氨基或烷基氨基,X2由以下公式(II)表示:(其中R4和R5是较低烷基基团,n是从2到4的整数)。】
  • [EN] 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS D'HÉTÉROCYCLYLE SUBSTITUÉS PAR UN 1-PHÉNYLE ET LEUR UTILISATION EN TANT QUE MODULATEURS DES RÉCEPTEURS DE LA PROSTAGLANDINE D2
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2012004722A1
    公开(公告)日:2012-01-12
    302 Abstract The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), O Y R 5 R 6 N R 2 R 3 R 4 X Z R 1 R 7 R 7 R 10 n (I) 5 wherein X, Y, Z, n, R 1, R 2, R 3, R 4, R 5, R 6, R 7 and R 10 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D 2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation. 10
    本发明涉及公式(I)的1-苯基取代的杂环基衍生物,其中X、Y、Z、n、R1、R2、R3、R4、R5、R6、R7和R10如描述中所述,并且它们作为前列腺素受体调节剂的用途,特别是作为前列腺素D2受体调节剂,在治疗各种前列腺素介导的疾病和紊乱中的用途,以及含有这些化合物的制药组合物和其制备方法。
  • Nitrogenous fused heteroaromatic ring derivative
    申请人:Takahashi Toshiyuki
    公开号:US20070167453A1
    公开(公告)日:2007-07-19
    The invention provides a compound or its pharmaceutically-acceptable salt of formula wherein A 1 is a hydrogen, etc.; j and k are 0 or 1; is a double bond, etc.; is a double bond, etc.; one of W 1 and W 2 is E-O—W, etc., and the other is a hydrogen atom, etc.; E is a divalent group derived from a benzene ring, etc., by removing two hydrogen atoms therefrom; W is a group of formula (II-1): which has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for prevention or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.
    本发明提供以下化合物或其药学上可接受的盐:其中A1为氢等;j和k为0或1;为双键等;为双键等;W1和W2中的一个为E-O-W等,另一个为氢原子等;E为由苯环衍生的二价基团,通过从中去除两个氢原子而得到;W为式(II-1)的基团:其具有组织胺H3受体拮抗作用或组织胺H3受体反向激动剂作用,并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
  • Quinazoline Derivative
    申请人:Mizutani Takashi
    公开号:US20080275069A1
    公开(公告)日:2008-11-06
    This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.
    本发明提供了式(I)的化合物或其药学上可接受的盐,其中R1代表较低的烷基等;R2和R3相同或不同,分别代表氢原子等;R4代表式(I)的取代基等;X1代表NH、O或S;Y代表N或C;Ar是由芳基衍生的二价取代基等,通过去除其中的两个氢原子而得到;环A表示5-或6-成员杂芳基基团;这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用,并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
  • Novel Benzoxathiine Derivative
    申请人:Mizutani Takashi
    公开号:US20100168156A1
    公开(公告)日:2010-07-01
    Disclosed is a compound represented by the formula (I) below and a pharmaceutically acceptable salt thereof. This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; X 1 represents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; X 2 represents a group represented by the following formula (II): (wherein R 4 and R 5 respectively represent a lower alkyl group or the like, and m represents a number of 2-4) or the like; one of X and Y represents an oxygen atom and the other represents a sulfanyl group or the like; and X 3 -X 6 respectively represent —CH—, a nitrogen atom or the like.
    揭示了一种由下式(I)表示的化合物及其药学上可接受的盐。该化合物可用于治疗肥胖症、糖尿病等疾病。[在式(I)中,Ar代表苯环或类似物;X1代表氮原子、硫原子或类似物;R1代表芳基或类似物;X2代表由以下式(II)表示的基团:(其中R4和R5分别表示低碳基或类似物,m表示2-4的数)或类似物;X和Y中的一个代表氧原子,另一个代表硫基或类似物;X3-X6分别表示-CH-,氮原子或类似物。
查看更多

同类化合物

阿法拉定A,TFA 钠(E)-2-氰基-3-[2,8-二(丙-2-基氧基)咪唑并[3,2-a]吡啶-3-基]丙-2-烯酸酯 诺白拉斯啶 苯酚,4-(5,6,7,8-四氢咪唑并[1,2-a]吡啶-8-基)- 米诺膦酸 米诺磷酸一水合物 硫酸利美戈潘 盐酸法屈唑半水合物 盐酸依格列汀 甲基咪唑并[1,5-A]吡啶-1-甲酸叔丁酯 甲基3-氨基咪唑并[1,2-a]吡啶-5-羧酸酯 甲基-(7-甲基咪唑并[1,2-A〕吡啶-2-基甲基)-胺 甲基-(5-甲基-咪唑并[1,2-A]吡啶-2-甲基)-胺 甲基 2-甲基咪唑并[1,2-a]吡啶-3-羧酸 环戊烷羧酸2-氨基-4-亚甲基-,(1R,2S)-(9CI) 环巴胺抑制剂1 泰妥拉唑 法倔唑盐酸盐 法倔唑 沃利替尼(对映异构体) 沃利替尼 氨基膦酸杂质14 巴马鲁唑 奥克塞米索 地扎胍宁甲磺酸盐 地扎胍宁 土大黄甙 咪唑磺隆 咪唑并吡啶-2-酮盐酸盐 咪唑并吡啶-2-酮 咪唑并二甲基吡啶 咪唑并[2,1-a]异喹啉-2(3H)-酮 咪唑并[1,5-a]吡啶-8-胺 咪唑并[1,5-a]吡啶-8-羧酸乙酯 咪唑并[1,5-a]吡啶-8-甲醛 咪唑并[1,5-a]吡啶-7-羧酸甲酯 咪唑并[1,5-a]吡啶-7-羧酸乙酯 咪唑并[1,5-a]吡啶-6-羧酸甲酯 咪唑并[1,5-a]吡啶-6-羧酸乙酯 咪唑并[1,5-a]吡啶-5-胺 咪唑并[1,5-a]吡啶-5-羧酸甲酯 咪唑并[1,5-a]吡啶-5-羧酸乙酯 咪唑并[1,5-a]吡啶-5-甲醛 咪唑并[1,5-a]吡啶-3-羧酸乙酯 咪唑并[1,5-a]吡啶-3-磺酰胺 咪唑并[1,5-a]吡啶-3-甲醛 咪唑并[1,5-a]吡啶-3(2H)-硫酮 咪唑并[1,5-a]吡啶-1-羧醛 咪唑并[1,5-a]吡啶-1-磺酰胺 咪唑并[1,5-a]吡啶-1-基-甲醇